Bolus Versus Continuous Enteral Tube Feeding

Sponsor
University Hospital Ostrava (Other)
Overall Status
Recruiting
CT.gov ID
NCT04080479
Collaborator
(none)
60
1
2
27
2.2

Study Details

Study Description

Brief Summary

Stress metabolisms induced by severe trauma, large abdominal surgery procedures, sepsis, etc. leads to metabolic changes, which increase energy expenditure, enhanced protein catabolism, insulin resistance. Muscle proteolysis is massively stimulated. Critically ill patients pay for survival with a loss of muscles. Enteral nutrition, especially protein delivery to critically ill, is very important for optimizing their outcome. Standard enteral feeding regiments are generally based on continuous feeding, which is thought to be better tolerated by critically ill patients with easier glycaemic control by continuous infusion of insulin, translated in less glycaemic variability. But this approach is not physiological, continuous feeding does not allow protein synthesis. Optimal protein synthesis requires a pulsatile increase in branched-chain amino acids. Bolus feeding activates the entrohormonal axis (bioactive peptides, insulin), and stimulates skeletal muscle synthesis to the maximum extent. The question is, whether bolus enteral feeding in critically ill patients with limited gastrointestinal function delivers a greater amount of protein, improves nutritional parameters, with higher quadriceps muscle layer thickness (QMLT) and muscle strength.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Quadriceps Muscle Layer Fitness
  • Diagnostic Test: Muscle Strength
  • Diagnostic Test: Acute Physiology and Chronic Health Evaluation
  • Diagnostic Test: Sequential Organ Failure Assessment
  • Diagnostic Test: Nutritional Risk Screening
  • Diagnostic Test: Energy and Protein Intake
N/A

Detailed Description

The trial has been designed in accordance with the Recommendations for Interventional Trials (SPIRIT 2013) and the Consolidated Standards for Reporting of Trials CONSORT guidelines.

Patients who meet the study inclusion criteria (severe trauma patients, surgical patients and medical patients with sepsis, with inserted nasogastric/nasoduodenal feed-ing tube) will be eligible to participate, especially patients who are mechanically ventilated. The last criterion is not a necessary precondition (a module of indirect calorimetry will be used in these patients). The necessary condition is the elimination of shock within 24 hours from the ICU admission and tolerance of trophic enteral feed-ing (20ml/hour) at for the period of at least 24 hours. Patients will be randomized in a ratio of 1:1 within 72 hours of their admission to receive bolus or continuous enteral feeding (sealed envelopes method). In both groups, the same goals of energy and protein will be observed (Day 1-2: E 15 kcal/kg/day, protein 0.8-1 g/kg/day; Day 3-4: E 20 kcal/kg/day, protein 1. 2 g/kg/day; Day ≥ 5: E 25 kcal/kg/day, protein 1.5-2 g/kg/day), according to protocol. The bolus enteral group will receive the amount of enteral nutrition in six boluses (per 60min dose), the continuous enteral group will receive the amount using a pump, within the timeframe of 6am-24pm. The need for parenteral nutrition will be determined by treating clinical staff independently to group allocation.

Demographic data collection: (weight, high, BMI) and conditions (trauma, surgical, medical patients), Acute Physiology and Chronic Health Evaluation (APACHE) Sequential Organ Failure Assessment (SOFA), Nutritional Risk Screening (NRS 2002).

Daily observations: glucose, mean glucose changes, insulin (IU/d), energy and protein intake (administered calories divided by the calculated energy expenditure and administered protein divided by calculated protein intake) - Adjusted/calculated energy and protein (%). Feeding intolerance (tolerating less than 40% of requirements via the enteral route for ≥ 3 days, diarrhea ≥ 500ml per day or five bowel actions). Mechanically ventilated patients (Resting Energy Expenditure (REE) and Respiratory Quotient (RQ) measured with indirect calorimetry) Day 1, 3, 5, 7: Nutritional parameters (serum albumin prealbumin, C-reactive protein (CRP), urine urea, N balance).

Day 1 and 7: Muscle layer thickness (QMLT by ultrasound measurement and mid-upper arm circumference) and muscle strength (dynamometer) from baseline to discharge. Outcomes of muscle strength/ultrasound and dynamometer) will be measured by an investigator blinded to the group allocation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study subjects will be randomized into one of the two study arms.The study subjects will be randomized into one of the two study arms.
Masking:
None (Open Label)
Masking Description:
No masking will be used in the study.
Primary Purpose:
Supportive Care
Official Title:
Bolus Versus Continuous Enteral Feeding in Critically Ill Patients
Actual Study Start Date :
Oct 1, 2019
Anticipated Primary Completion Date :
Sep 30, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bolus enteral feeding

The patients randomized into this study arm will receive bolus enteral feeding. The study subjects will undergo the following interventions: Quadriceps Muscle Layer Fitness measurement Muscle Strength measurement Acute Physiology and Chronic Health Evaluation Sequential Organ Failure Assessment Nutritional Risk Screening Energy and Protein Intake

Diagnostic Test: Quadriceps Muscle Layer Fitness
The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
Other Names:
  • QMLF
  • Diagnostic Test: Muscle Strength
    All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.

    Diagnostic Test: Acute Physiology and Chronic Health Evaluation
    All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
    Other Names:
  • APACHE
  • Diagnostic Test: Sequential Organ Failure Assessment
    All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
    Other Names:
  • SOFA
  • Diagnostic Test: Nutritional Risk Screening
    All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
    Other Names:
  • NSR
  • Diagnostic Test: Energy and Protein Intake
    The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.

    Experimental: Continuous enteral feeding

    The patients randomized into this study arm will receive bolus enteral feeding. The study subjects will undergo the following interventions: Quadriceps Muscle Layer Fitness measurement Muscle Strength measurement Acute Physiology and Chronic Health Evaluation Sequential Organ Failure Assessment Nutritional Risk Screening Energy and Protein Intake

    Diagnostic Test: Quadriceps Muscle Layer Fitness
    The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
    Other Names:
  • QMLF
  • Diagnostic Test: Muscle Strength
    All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.

    Diagnostic Test: Acute Physiology and Chronic Health Evaluation
    All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
    Other Names:
  • APACHE
  • Diagnostic Test: Sequential Organ Failure Assessment
    All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
    Other Names:
  • SOFA
  • Diagnostic Test: Nutritional Risk Screening
    All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
    Other Names:
  • NSR
  • Diagnostic Test: Energy and Protein Intake
    The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.

    Outcome Measures

    Primary Outcome Measures

    1. Change in nutritional parameters - serum albumin [7 days]

      The development of the serum albumin levels in g/dL will be observed.

    2. Change in nutritional parameters - prealbumin [7 days]

      The development of the serum albumin levels in mg/dL will be observed.

    3. Change in inflammatory parameters - C-reactive protein (CRP) [7 days]

      The development of inflammatory parameters in mg/L will be observed.

    4. Change in muscle mass [7 days]

      The development of muscle mass (circumference in centimetres) will be measured.

    5. Change in muscle strength [7 days]

      The development of muscle strength (in kilograms) will be measured.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • polytrauma

    • major abdominal surgery

    • sepsis

    • ICU stay

    • enteral feeding tube

    • artificial ventilation

    Exclusion Criteria:
    • contraindication of enteral feeding

    • infaust prognosis

    • prolonged shock (more than 24 hours)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Ostrava Ostrava Moravian-Silesian Region Czechia 70852

    Sponsors and Collaborators

    • University Hospital Ostrava

    Investigators

    • Principal Investigator: Marcela Káňová, MD,PhD, University Hospital Ostrava

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Hospital Ostrava
    ClinicalTrials.gov Identifier:
    NCT04080479
    Other Study ID Numbers:
    • FNO-KARIM-12-Enteral_Feeding
    First Posted:
    Sep 6, 2019
    Last Update Posted:
    Feb 17, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital Ostrava

    Study Results

    No Results Posted as of Feb 17, 2021